Episode 57
Biotech Hangout
00:00
BCMA Carti in Multiple Myeloma
The latest data in the earliest line of therapy that a BCMA Carti has been tested in multiple myeloma. That's already on the market for more advanced late stage refractory disease. There are still questions about how much can they manufacture. But, you know, I'd rather have a manufacturing capacity issue and fantastic data than the other way around.
Transcript
Play full episode
